Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 240 clinical trials
A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised …

vincristine
inotuzumab
doxorubicin
dexamethasone
imatinib
  • 27 views
  • 27 Jan, 2021
  • 102 locations
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

The study is being conducted to evaluate the safety and efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody in subjects with advanced thyroid

thyroid carcinoma
cancer
medullary thyroid carcinoma
measurable disease
filgrastim
  • 12 views
  • 27 Jan, 2021
  • 1 location
Assessing An Oral Janus Kinase Inhibitor AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20~40 patients will be subsequently …

peripheral t-cell lymphoma
t-cell lymphoma
systemic therapy
measurable disease
  • 0 views
  • 27 Jan, 2021
  • 22 locations
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.

  • 0 views
  • 24 Feb, 2021
  • 4 locations
Study of TG-1701 an Irreversible Bruton's Tyrosine Kinase Inhibitor in Patients With B-Cell Malignancies

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies

cancer
tyrosine
b-cell lymphoma
lymphoma
  • 117 views
  • 13 Feb, 2021
  • 15 locations
A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies

This is a Phase I, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of a novel BTK inhibitor, ICP-022. During this study, dose escalation will be conducted in patients diagnosed with refractory/relapsed (r/r) B-cell malignancies including only patients with Grades1-3a follicular lymphoma (FL); marginal zone lymphoma (MZL); …

hepatitis b core antibody
hepatitis b surface antigen
chronic lymphocytic leukemia
cancer
ct scan
  • 7 views
  • 28 Jan, 2021
  • 8 locations
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

The study will include 30 elderly patients age 60-85 with primary CNS DLBCL . Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will …

methotrexate
maintenance treatment
ibrutinib
neutrophil count
imbruvica
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Background Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, …

progressive disease
cardiovascular disease
cancer
antiretroviral
ct scan
  • 11 views
  • 26 Jan, 2021
  • 1 location
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in

  • 10 views
  • 23 Jan, 2021
  • 8 locations
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment

metastatic solid tumor
cancer
neutrophil count
solid tumor
advanced cancer
  • 20 views
  • 21 Jan, 2021
  • 1 location